LYBALVI
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Focus of Study is on Healthy Lactating Women
Conditions
Focus of Study is on Healthy Lactating Women
Trial Timeline
Sep 14, 2022 → Nov 19, 2022
NCT ID
NCT05547100About LYBALVI
LYBALVI is a phase 1 stage product being developed by Alkermes for Focus of Study is on Healthy Lactating Women. The current trial status is completed. This product is registered under clinical trial identifier NCT05547100. Target conditions include Focus of Study is on Healthy Lactating Women.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05547100 | Phase 1 | Completed |
Competing Products
5 competing products in Focus of Study is on Healthy Lactating Women
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 2 | 52 |
| Nascobal nasal spray (cyanocobalamin, USP) + Vitamin B12-ratiopharm N, injection solution | Swedish Orphan Biovitrum | Phase 1 | 32 |
| danegaptide + Placebo | Zealand Pharma | Phase 2 | 49 |
| S303 Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells (RBCs) | Cerus | Phase 2 | 44 |
| S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - Control | Cerus | Phase 3 | 69 |